Otsuka Pharmaceutical Company, Limited

Nobuhiro Ikei

Makoto Inada

Hideji Nonomura

Yasuo Irie

Tsuyoshi Hirose

Fumio Shimizu

Keigo Yamada

Kenichi Imagawa

Tetsuya Tachikawa

Masateru Miyake

Atsunari Noda

Shinsuke Nakagawa

Masahiro Kajiwara

Etsuro Hashimura

Atunari Noda

Jun-Ichi Kunizaki

Kuniaki Natsume

The present invention provide a method for measuring and assessing the capacity in an individual subject to metabolize a variety of fluorouracil drugs, such as 5-fluorouracil, which are degraded in the pyrimidine metabolic pathway, and a preparation useful for the measurement and assessment. The present invention can be carried out by: administering a preparation for determining pyrimidine metabolic capacity comprising as an active ingredient a pyrimidine compound or pyrimidine metabolic compound that acts as a substrate for a pyrimidine metabolizing enzyme, in which at least one of the carbon, oxygen, and nitrogen atoms is labeled with an isotope; and assessing in vivo pyrimidine metabolic capacity based on the behavior of an excreted metabolite.

Preparation for determining pyrimidine metabolic capacity

Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Preparations for evaluating eliminative ability of stomach

The present invention provide a method for assessing the sensitivity to a pyrimidine drug such as 5-FU which is degraded in the pyrimidine metabolic pathway, specifically in vivo pyrimidine metabolizing activity, of an individual subject; and a preparation useful for the assessment. The present invention can be carried out by: administering a preparation comprising as an active ingredient a pyrimidine compound or its metabolite which acts as a substrate for a pyrimidine metabolizing enzyme, in which compound or metabolite at least one of C, O and N is labeled with an isotope; and assessing in vivo pyrimidine metabolizing activity based on the amount of excreted metabolite.

Composition for determining pyrimidine metabolizing activity

Diagnostic and diagnosis method for central nervous abnormality and

An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide represented by formula (1):

Human leukemia virus-related peptides, a process for production thereof,

Growing community of inventors

Tokushima, Japan

Nobuhiro Ikei